Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02790671 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects

A Phase 1 study of Pharmacokinetics, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
1
Study location

NCT02790671 is a Phase 1 study of Pharmacokinetics that has completed, run by Daiichi Sankyo. The registered enrollment target is 26 participants, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02790671, a Phase 1 study of Pharmacokinetics, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

Study will assess the effects of itraconazole on the pharmacokinetic (PK) parameters of single-dose DS-8500a in healthy subjects. This is an open-label study in healthy subjects.

Conditions Studied

Interventions

  • DRUG Itraconazole
  • DRUG DS-8500a

Study Locations (1)

Texas

  • Worldwide Clinical Trials - San Antonio

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2016-05
Est. Completion 2016-06
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

What the Registry Record Tells You About NCT02790671

The ClinicalTrials.gov registry entry for NCT02790671 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (57% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which Itraconazole is the first listed.

NCT02790671 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02790671 about?

NCT02790671 is a clinical study titled "A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects". Study will assess the effects of itraconazole on the pharmacokinetic (PK) parameters of single-dose DS-8500a in healthy subjects. This is an open-label study in healthy subjects.

What is the current status of trial NCT02790671?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2016-05. Estimated completion is 2016-06.

What conditions does trial NCT02790671 study?

This clinical trial studies the following conditions: Pharmacokinetics.

What interventions are being tested in trial NCT02790671?

The interventions under investigation include: Itraconazole (DRUG), DS-8500a (DRUG).

Who is sponsoring clinical trial NCT02790671?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02790671 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pharmacokinetics

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.